Bartosz Hudzik: Better Control, Similar Tolerability With Quadruple Therapy in Resistant Hypertension
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared a post on LinkedIn about a recent article by Stefano Taddei et al, published in European Society of Cardiology:
”Resistant hypertension is often treated as a dosing problem.
But what if it’s actually a strategy problem?
Patients with true resistant hypertension face markedly higher risks of stroke, heart failure, kidney disease, and death — yet many remain on prolonged triple therapy despite uncontrolled BP.
The Phase 3 QUADRO trial challenges that inertia.
Switching patients from standard triple therapy to the first full-dose quadruple single-pill combination (adding bisoprolol) delivered:
- −8 mmHg additional systolic BP reduction in just 8 weeks
- Confirmed improvement on 24-hour ambulatory monitoring
- No serious safety concerns
- A single pill instead of therapeutic escalation by fragmentation
In other words: better control, similar tolerability, potentially better adherence.
If resistant hypertension drives disproportionate cardiovascular risk, should we be escalating faster — and simplifying sooner?”
Title: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial
Authors: Stefano Taddei, Krzysztof Narkiewicz, Stéphanie Bricout-Hennel, Parvoleta Petrova, Cécile Batailler, Roland Asmar
Read the Full Article on European Society of Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress